FASEB J. Thermo Fisher Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Manev, H.
Right arrow Articles by Joo, J. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Manev, H.
Right arrow Articles by Joo, J. Y.

The FASEB Journal, Vol 10, 1546-1551, Copyright © 1996 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats

H Manev, T Uz, A Kharlamov and JY Joo
The Psychiatric Institute, University of Illinois, Chicago 60612, USA.

The pineal hormone melatonin is neuroprotective in vitro, and in vivo it is neuroprotective when given in pharmacological doses. Consequently, it has been hypothesized that with aging, as circulating levels of melatonin in mammals normally decrease, the brain might be at increased risk of neurodegeneration. However, direct evidence that melatonin deficiency leads to increased brain vulnerability is still lacking. We created melatonin deficiency in rats by pinealectomy and induced neurodegeneration by two models of focal brain ischemia/stroke and by glutamate receptor-mediated, epilepsy-like seizures. We observed greater neurodegeneration in melatonin-deficient animals than in controls. Our results suggest that endogenous melatonin may play a neuroprotective role, and that melatonin deficiency might be a pathophysiological mechanism in neurodegenerative diseases.


This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
R. J. Reiter, D.-x. Tan, J. Leon, U. Kilic, and E. Kilic
When Melatonin Gets on Your Nerves: Its Beneficial Actions in Experimental Models of Stroke
Experimental Biology and Medicine, February 1, 2005; 230(2): 104 - 117.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
R. J. REITER, D.-X. TAN, and M. A. PAPPOLLA
Melatonin Relieves the Neural Oxidative Burden that Contributes to Dementias
Ann. N.Y. Acad. Sci., December 1, 2004; 1035(1): 179 - 196.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
R. J. REITER, R. M. SAINZ, S. LOPEZ-BURILLO, J. C. MAYO, L. C. MANCHESTER, and D. X. TAN
Melatonin Ameliorates Neurologic Damage and Neurophysiologic Deficits in Experimental Models of Stroke
Ann. N.Y. Acad. Sci., May 1, 2003; 993(1): 35 - 47.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
Z. Pei, S. F. Pang, and R. T. F. Cheung
Administration of Melatonin After Onset of Ischemia Reduces the Volume of Cerebral Infarction in a Rat Middle Cerebral Artery Occlusion Stroke Model
Stroke, March 1, 2003; 34(3): 770 - 775.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Wolfler, P. M. Abuja, W. Linkesch, K. Schauenstein, P. M. Liebmann, Vijayalaxmi, C. R. Thomas Jr, R. J. Reiter, and T. S. Herman
Questionable Benefit of Melatonin for Antioxidant Pharmacologic Therapy
J. Clin. Oncol., October 1, 2002; 20(19): 4127 - 4129.
[Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
Y. Gilgun-Sherki, Z. Rosenbaum, E. Melamed, and D. Offen
Antioxidant Therapy in Acute Central Nervous System Injury: Current State
Pharmacol. Rev., June 1, 2002; 54(2): 271 - 284.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
M. Karbownik and R. J. Reiter
Antioxidative Effects of Melatonin in Protection Against Cellular Damage Caused by Ionizing Radiation
Experimental Biology and Medicine, October 1, 2000; 225(1): 9 - 22.
[Abstract] [Full Text]

Home page
 FASEB J.Home page
C. HARMS, M. LAUTENSCHLAGER, A. BERGK, D. FREYER, M. WEIH, U. DIRNAGL, J. R. WEBER, and H. HÖRTNAGL
Melatonin is protective in necrotic but not in caspase-dependent, free radical-independent apoptotic neuronal cell death in primary neuronal cultures
FASEB J, September 1, 2000; 14(12): 1814 - 1824.
[Abstract] [Full Text]

Home page
 Arch NeurolHome page
N. Delanty and M. A. Dichter
Antioxidant Therapy in Neurologic Disease
Arch Neurol, September 1, 2000; 57(9): 1265 - 1270.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
C. V. BORLONGAN, M. YAMAMOTO, N. TAKEI, M. KUMAZAKI, C. UNGSUPARKORN, H. HIDA, P. R. SANBERG, and H. NISHINO
Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia
FASEB J, July 1, 2000; 14(10): 1307 - 1317.
[Abstract] [Full Text]

Home page
 FASEB J.Home page
H. MANEV, T. UZ, K. SUGAYA, and T. QU
Putative role of neuronal 5-lipoxygenase in an aging brain
FASEB J, July 1, 2000; 14(10): 1464 - 1469.
[Abstract] [Full Text]

Home page
 Alcohol AlcoholHome page
G. H. El-Sokkary, R. J. Reiter, D.-X. Tan, S. J. Kim, and J. Cabrera
INHIBITORY EFFECT OF MELATONIN ON PRODUCTS OF LIPID PEROXIDATION RESULTING FROM CHRONIC ETHANOL ADMINISTRATION
Alcohol Alcohol., November 1, 1999; 34(6): 842 - 850.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
B. Ancona, L. Facci, D. Franceschini, and P. Giusti
Melatonin prevents the delayed death of hippocampal neurons induced by enhanced excitatory neurotransmission and the nitridergic pathway
FASEB J, June 1, 1998; 12(9): 725 - 731.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by The Federation of American Societies for Experimental Biology.